Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs 10X Genomics Inc (TXG) Price & Performance

First Trust NASDAQ Clean Edge Green Energy Idx FdTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Clean Edge Green Energy Idx Fd vs 10X Genomics Inc — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $49.35, while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.

QCLNTXG
Sector
Sector/ThematicHealth
52-Week High
$68.47$67.29
52-Week Low
$37.69$11.34
Market Cap
$8.55B
Enterprise Value
$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN trades at $50.57, up 2.31% today, with a bullish technical signal overall despite bearish moving averages. The ETF is positioned to benefit from global renewable energy acceleration driven by geopolitical tensions and rising data center power demand. Recent news highlights its sensitivity to U.S. political outcomes and federal clean energy policy, with historical outperformance ahead of midterm elections.

The outlook is supported by structural tailwinds in clean energy adoption, but risks include regulatory uncertainty and permit delays under current U.S. administration. Investment appeal hinges on policy continuity and execution of global renewable projects, with volatility expected around political developments.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ Clean Edge Green Energy Idx Fd

QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.

Read more on QCLN

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG